Developing a new treatment for aldicarb poisoning
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning
This study is working on a new treatment that helps people who have been exposed to a dangerous pesticide called aldicarb, by creating a special enzyme that can help restore the body's ability to function normally after exposure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10917295 on NIH RePORTER |
What this research studies
This research focuses on creating a long-acting enzyme that can effectively counteract the toxic effects of aldicarb, a highly toxic pesticide. The approach involves understanding how aldicarb inhibits a critical enzyme in the body, acetylcholinesterase, and developing a medical countermeasure that can restore its function. By using advanced biochemical techniques, the research aims to improve treatment options for individuals exposed to aldicarb, particularly in emergency situations. The study will involve both laboratory experiments and potential animal models to evaluate the effectiveness of the new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals who have been exposed to aldicarb or are at risk of exposure due to environmental or occupational factors.
Not a fit: Patients who have not been exposed to aldicarb or who have other unrelated medical conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for patients suffering from aldicarb poisoning, potentially saving lives and improving recovery outcomes.
How similar studies have performed: While there has been significant research on treatments for organophosphate poisoning, this specific approach to aldicarb poisoning is relatively novel and has not been extensively tested.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Zheng, Fang — University of Kentucky
- Study coordinator: Zheng, Fang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.